Judith Balmañà

18.9k total citations · 4 hit papers
179 papers, 6.5k citations indexed

About

Judith Balmañà is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Judith Balmañà has authored 179 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 92 papers in Genetics and 62 papers in Molecular Biology. Recurrent topics in Judith Balmañà's work include BRCA gene mutations in cancer (89 papers), PARP inhibition in cancer therapy (57 papers) and Genetic factors in colorectal cancer (47 papers). Judith Balmañà is often cited by papers focused on BRCA gene mutations in cancer (89 papers), PARP inhibition in cancer therapy (57 papers) and Genetic factors in colorectal cancer (47 papers). Judith Balmañà collaborates with scholars based in Spain, United States and United Kingdom. Judith Balmañà's co-authors include Orland Dı́ez, Susan M. Domchek, Ronnie Shapira‐Frommer, Bella Kaufman, Michael Friedländer, Gillian Mitchell, M. William Audeh, Niklas Loman, Georgeta Fried and Rita K. Schmutzler and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Judith Balmañà

171 papers receiving 6.4k citations

Hit Papers

Olaparib Monotherapy in Patients With Advanced Cancer and... 2014 2026 2018 2022 2014 2019 2016 2022 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. Journal of Clinical Oncology profile →
  2. A decade of clinical development of PARP inhibitors in perspective
    2019 495 citations Joaquı́n Mateo, Christopher J. Lord et al. Annals of Oncology profile →
  3. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
    2016 266 citations Shani Paluch–Shimon, Fátima Cardoso et al. Annals of Oncology profile →
  4. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
    2022 98 citations Cristiana Sessa, Judith Balmañà et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judith Balmañà Spain 36 3.9k 2.6k 2.4k 1.6k 1.6k 179 6.5k
Gillian Mitchell Australia 29 3.5k 0.9× 2.6k 1.0× 2.5k 1.0× 1.4k 0.9× 739 0.5× 113 6.3k
Niklas Loman Sweden 27 3.4k 0.9× 2.6k 1.0× 2.2k 0.9× 1.7k 1.1× 574 0.4× 52 5.8k
Rinat Yerushalmi Israel 27 4.4k 1.1× 2.2k 0.9× 1.2k 0.5× 2.3k 1.4× 694 0.4× 119 6.7k
Nadine Tung United States 53 5.7k 1.4× 3.9k 1.5× 5.9k 2.5× 3.8k 2.3× 1.6k 1.0× 190 11.3k
Anitra Fielding United Kingdom 24 3.7k 0.9× 1.9k 0.7× 1.1k 0.4× 699 0.4× 356 0.2× 57 5.0k
David S.P. Tan Singapore 37 2.5k 0.6× 2.2k 0.8× 664 0.3× 1.5k 0.9× 579 0.4× 181 5.1k
Hatem A. Azim Belgium 36 3.6k 0.9× 1.3k 0.5× 760 0.3× 1.6k 1.0× 394 0.3× 120 5.5k
Werner Meier Germany 32 3.3k 0.8× 1.6k 0.6× 1.0k 0.4× 531 0.3× 426 0.3× 166 5.8k
Antonis C. Antoniou United Kingdom 42 2.1k 0.5× 2.0k 0.8× 4.6k 1.9× 1.8k 1.1× 1.2k 0.8× 130 6.8k
Paul DiSilvestro United States 33 2.0k 0.5× 1.3k 0.5× 715 0.3× 860 0.5× 719 0.5× 159 6.4k

Countries citing papers authored by Judith Balmañà

Since Specialization
Citations

This map shows the geographic impact of Judith Balmañà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Balmañà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Balmañà more than expected).

Fields of papers citing papers by Judith Balmañà

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Balmañà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Balmañà. The network helps show where Judith Balmañà may publish in the future.

Co-authorship network of co-authors of Judith Balmañà

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Balmañà. A scholar is included among the top collaborators of Judith Balmañà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Balmañà. Judith Balmañà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rowlands, Charlie F, Judith Balmañà, Susan M. Domchek, et al.. (2024). Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Annals of Oncology. 35(10). 892–901. 7 indexed citations
2.
Lambertini, Matteo, Eva Blondeaux, Elisa Agostinetto, et al.. (2024). Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.. Journal of Clinical Oncology. 42(16_suppl). 10503–10503. 1 indexed citations
3.
Pal, Tuya, Katherine Schon, Judith Balmañà, et al.. (2024). Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 27(1). 101243–101243. 6 indexed citations
4.
Feliubadaló, Lídia, Jesús Del Valle, Sara González, et al.. (2024). Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data. Journal of Molecular Diagnostics. 26(8). 727–738. 1 indexed citations
5.
Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations
6.
Cajal, Teresa Ramón y, Marta Pineda, Elena Aguirre, et al.. (2023). SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 25(9). 2627–2633. 4 indexed citations
7.
8.
Murillo, Laura, Judith Balmañà, Alba de Pablo García‐Cuenca, et al.. (2021). Post-hematopoietic stem cell transplant squamous cell carcinoma in patients with Fanconi anemia: a dreadful enemy. Clinical & Translational Oncology. 24(2). 388–392. 7 indexed citations
9.
Mateo, Joaquı́n, Christopher J. Lord, Violeta Serra, et al.. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology. 30(9). 1437–1447. 495 indexed citations breakdown →
10.
Turner, Nicholas C., Melinda L. Telli, Hope S. Rugo, et al.. (2018). A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research. 25(9). 2717–2724. 88 indexed citations
11.
Rutgers, Emiel J., Judith Balmañà, Marc Beishon, et al.. (2018). European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer. European Journal of Cancer. 106. 45–53. 12 indexed citations
12.
Singer, Christian F., Judith Balmañà, Nicole Bürki, et al.. (2018). Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. European Journal of Cancer. 106. 54–60. 25 indexed citations
13.
Kristeleit, Rebecca, Geoffrey I. Shapiro, Howard A. Burris, et al.. (2017). A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research. 23(15). 4095–4106. 186 indexed citations
14.
15.
Paluch–Shimon, Shani, Fátima Cardoso, Cristiana Sessa, et al.. (2016). Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 27(suppl 5). v103–v110. 266 indexed citations breakdown →
16.
Juvekar, Ashish, Laura N. Burga, Hai Hu, et al.. (2012). Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. Cancer Discovery. 2(11). 1048–1063. 336 indexed citations
17.
Kastrinos, Fay, Ewout W. Steyerberg, Judith Balmañà, et al.. (2012). Comparison of the clinical prediction model PREMM 1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut. 62(2). 272–279. 39 indexed citations
18.
Balmañà, Judith, Orland Dı́ez, Isabel T. Rubio, & M. Castiglione. (2010). BRCA in breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 21. v20–v22. 164 indexed citations
19.
Balmañà, Judith, Antoni Castells, & Andrés Cervantes. (2010). Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Annals of Oncology. 21. v78–v81. 29 indexed citations
20.
Bandipalliam, Prathap, Judith Balmañà, & Sapna Syngal. (2004). Comprehensive genetic and endoscopic evaluation may be necessary to distinguish sporadic versus familial adenomatous polyposis–associated abdominal desmoid tumors. Surgery. 135(6). 683–689. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gillian Mitchell Breakdown of academic impact, for papers by Niklas Loman Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Nadine Tung Breakdown of academic impact, for papers by Anitra Fielding Breakdown of academic impact, for papers by David S.P. Tan Breakdown of academic impact, for papers by Hatem A. Azim Breakdown of academic impact, for papers by Werner Meier Breakdown of academic impact, for papers by Antonis C. Antoniou Breakdown of academic impact, for papers by Paul DiSilvestro
Rankless by CCL
2026